Industries
Diagnostics
All research in Diagnostics — 3 reports.
46/100
Guardant Health: A Rerating Built on a Company in Transition
Guardant Health is a blood-based oncology diagnostics company whose economic center still sits in advanced-cancer therapy selection while its upside narrative has shifted toward Shield, a colorectal-cancer screening test that just won UnitedHealth coverage for 100 million lives. 2025 revenue reached 982 million USD, up 33% year on year, with non-GAAP gross margin improving from 62% to 66%, yet the company still posts negative owner earnings and trades near 17x forward EV/sales, above larger and cash-generative peer Natera. Rating Watch: an excellent liquid-biopsy franchise, but the stock already prices in broad Shield adoption and a faster profit path than has been proven, with the ideal buy zone at 68 to 74 dollars.
44/100
Labcorp Holdings: A Value-Investing Deep Dive
One of the two dominant players combining a scaled clinical-testing network with biopharma laboratory services; cash flow is real, but pricing power is constrained by payers and regulation. At roughly $262.75 the stock sits inside a fair-value band of $220-280 with no obvious margin of safety, so the rating is Watch, with an ideal buy range of $180-210.
41/100
Quest Diagnostics: A Long-Term Business-Owner Investment Analysis
One of the two national clinical-lab duopolists, with steady demand and solid cash flow but weak unit pricing power; at roughly $196.2 and a trailing P/E of about 21.7x, it sits at the upper end of a fair intrinsic-value range of $180-205, leaving no clear margin of safety, so the rating is Watch.